Apexigen, Inc. Common Stock
APGN
APGN was delisted on the 22nd of August, 2023.
27 hedge funds and large institutions have $37.5M invested in Apexigen, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 16 closing their positions.
13% more capital invested
Capital invested by funds: $33.2M → $37.5M (+$4.22M)
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
33% less funds holding
Funds holding: 40 → 27 (-13)
81% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MSU
Mizuho Securities USA
New York
|
+$3.8M |
| 2 |
CAC
Cowen and Company
New York
|
+$3.04M |
| 3 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
+$1.73M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$966K |
| 5 |
MC
Meteora Capital
Boca Raton,
Florida
|
+$857K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$1.48M |
| 2 |
BCM
Basso Capital Management
Stamford,
Connecticut
|
-$1.46M |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$1.03M |
| 4 |
RCM
Rivernorth Capital Management
West Palm Beach,
Florida
|
-$1.01M |
| 5 |
FTCM
Fir Tree Capital Management
New York
|
-$450K |
APGN Hedge Fund Activity: Q2 2022 in Review
27 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Apexigen, Inc. Common Stock (APGN) for Q2 2022, worth a combined $37.5M — up 13% from $33.2M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of APGN and 3 opened new positions — a net loss of 13 holders — while 8 trimmed existing stakes and 8 added.
The largest buyer was Mizuho Securities USA, adding an estimated $3.8M. The largest seller was Periscope Capital, cutting an estimated $1.48M.
- 27 institutional investors held Apexigen, Inc. Common Stock (APGN) as of Q2 2022, down from 40 in Q1 2022.
- Funds reported $37.5M of Apexigen, Inc. Common Stock stock for Q2 2022, up 13% quarter-over-quarter.
- 3 funds opened new Apexigen, Inc. Common Stock positions in Q2 2022 and 16 closed out, a net change of -13 holders.
- The largest Apexigen, Inc. Common Stock buyer in Q2 2022 was Mizuho Securities USA, an estimated $3.8M added.
- The largest Apexigen, Inc. Common Stock seller in Q2 2022 was Periscope Capital, an estimated $1.48M sold.
Based on aggregated 13F filings for Q2 2022.